Skip to content

Abbott ABT Treasury Stock

Treasury Stock at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$1.01B+30.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$75.86B+0.2%
Artivion logo
ArtivionAORT
$14.65M0.0%
DexCom logo
DexComDXCM
$2.12B+34.1%
Edwards Lifesciences logo
Edwards LifesciencesEW
$7.51B+16.5%
AngioDynamics logo
AngioDynamicsANGO
$7.38M0.0%

Other financials

Income statement

See full
Revenue$12.6B+13.0%
Gross profit$7.3B+15.6%
Operating income$1.7B-17.5%
Net income$928.0M-47.8%
EPS (diluted)$0.53-47.5%

Balance sheet

See full
Cash & equivalents$6.8B+4.1%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$179.51B-18.3%
Enterprise value$206.76B-13.1%
P/E33.1×+17.4×
P/S3.9×-1.2×

Profitability

See full
Gross margin56.6%+0.6pp
Operating margin15.8%-1.7pp
Net margin11.6%-20.8pp
FCF margin16.3%+0.6pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's treasury stock?
Abbott (ABT) reported treasury stock of $16.94B in Q1 2026.
How has Abbott's treasury stock changed year-over-year?
Abbott's treasury stock increased by 1.9% year-over-year, from $16.61B to $16.94B.
What is the long-term trend for Abbott's treasury stock?
Over 5 years (2020 to 2025), Abbott's treasury stock has grown at a 11.3% compound annual growth rate (CAGR), from $10.04B to $17.18B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.